TNF and uveitis: In terms of anti-TNF choice, a relatively recent comparative study in 177 BD patients with refractory uveitis showed that both infliximab and adalimumab led to favourable outcomes during a one-year follow-up; however, improvement in ophthalmic examinations was more remarkable after one year of treatment with adalimumab [77].